With front-line treatment of AML, plus MDS, its market potential is much bigger than that of SNSS, and yet market cap of CYCC is merely 24% of SNSS'. I firmly believe that the market cap of CYCC should be easily reach $140m, or $15/share very soon.
I also don't understand why this company trades at this level. There is going to be a relief valve blow soon, and suddenly this will be $15 bucks or higher... Why isn't CELG buying this with their pocket change, and being done with it? They could offer $20 bucks a share, and it wouldn't even show on their balance sheets..
The fact that the market cap is less than 50 million for a co with so much potential is what surprises me. Why hasn't any of the big pharmas jumped to date to buy it out. I mean 140 million with 15/share is coin change for some of these big pharmas? So, what is the story of shorts who keep shorting it with so much promise? Do they know something?